United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dexlansoprazole (unii: uye4t5i70x) (dexlansoprazole - unii:uye4t5i70x) - dexlansoprazole 30 mg - kapidex is indicated for healing of all grades of erosive esophagitis (ee) for up to 8 weeks. kapidex is indicated to maintain healing of ee for up to 6 months. kapidex is indicated for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks. kapidex is contraindicated in patients with known hypersensitivity to any component of the formulation [see description (11)] . hypersensitivity and anaphylaxis have been reported with kapidex use [see adverse reactions (6.1)] . teratogenic effects pregnancy category b. there are no adequate and well-controlled studies with dexlansoprazole in pregnant women. there were no adverse fetal effects in animal reproduction studies of dexlansoprazole in rabbits. because animal reproduction studies are not always predictive of human response, kapidex should be used during pregnancy only if clearly needed. a reproduction study conducted in rabbits at oral dexlansoprazole doses up to 30 mg per kg per day (approximately 9-

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - dexlansoprazole (unii: uye4t5i70x) (dexlansoprazole - unii:uye4t5i70x) - dexlansoprazole 60 mg - dexilant is indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (ee) for up to eight weeks. dexilant is indicated in patients 12 years of age and older to maintain healing of ee and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. dexilant is indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (gerd) for four weeks. risk summary there are no studies with dexlansoprazole use in pregnant women to inform a drug-associated risk. dexlansoprazole is the r-enantiomer of lansoprazole, and published observational studies of lansoprazole use during pregnancy did not demonstrate an association of adverse pregnancy-related outcomes with lansoprazole (see data) . in animal reproduction studies, oral administration of lansoprazole to rats during organogenesis through lactation at 1.8 times the maximum recommended human dexlansoprazo

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - dexlansoprazole (unii: uye4t5i70x) (dexlansoprazole - unii:uye4t5i70x) - dexlansoprazole 30 mg - dexilant is indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (ee) for up to eight weeks. dexilant is indicated in patients 12 years of age and older to maintain healing of ee and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. dexilant is indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (gerd) for four weeks. - dexilant is contraindicated in patients with known hypersensitivity to any component of the formulation [see description (11)] . hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis and urticaria [see warnings and precautions (5.2), adverse reactions (6)] . - ppis, including dexilant, are contraindicated with rilpivirine-containing products [see drug interactions (7)] . risk summary there are no studies with dexlansoprazole us

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dexlansoprazole (unii: uye4t5i70x) (dexlansoprazole - unii:uye4t5i70x) - dexlansoprazole 60 mg - dexilant is indicated for healing of all grades of erosive esophagitis (ee) for up to 8 weeks. dexilant is indicated to maintain healing of ee and relief of heartburn for up to 6 months. dexilant is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (gerd) for 4 weeks. dexilant is contraindicated in patients with known hypersensitivity to any component of the formulation [see description (11)] . hypersensitivity and anaphylaxis have been reported with dexilant use [see adverse reactions (6.1)] . teratogenic effects pregnancy category b. there are no adequate and well-controlled studies with dexlansoprazole in pregnant women. there were no adverse fetal effects in animal reproduction studies of dexlansoprazole in rabbits. because animal reproduction studies are not always predictive of human response, dexilant should be used during pregnancy only if clearly needed. a reproduction study conducted in rabbits at oral dexlansoprazole doses up to approxi

Israel - English - Ministry of Health

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 30 mg - dexlansoprazole - dexilant 30 is indicated in adults and in adolescents aged 12 to 17 years for the following:• maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn• short-term treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (gord).

Israel - English - Ministry of Health

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 60 mg - dexlansoprazole - dexilant 60 is indicated in adults and in adolescents aged 12 to 17 years for the following:• treatment of erosive reflux oesophagitis

Israel - English - Ministry of Health

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 30 mg - dexlansoprazole - dexilant 30 is indicated in adults and in adolescents aged 12 to 17 years for the following:• maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn• short-term treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (gord).

Israel - English - Ministry of Health

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 60 mg - dexlansoprazole - dexilant 60 is indicated in adults and in adolescents aged 12 to 17 years for the following:• treatment of erosive reflux oesophagitis

United States - English - NLM (National Library of Medicine)

a-s medication solutions - dexlansoprazole (unii: uye4t5i70x) (dexlansoprazole - unii:uye4t5i70x) - dexilant is indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (ee) for up to eight weeks. dexilant is indicated in patients 12 years of age and older to maintain healing of ee and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age. dexilant is indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (gerd) for four weeks. - dexilant is contraindicated in patients with known hypersensitivity to any component of the formulation [see description (11)] . hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis and urticaria [see warnings and precautions (5.2), adverse reactions (6)] . - ppis, including dexilant, are contraindicated with rilpivirine-containing products [see drug interactions (7)] . risk summary there are no studies with dexlansoprazole us

Bangladesh - English - DGDA (Directorate General of Drug Administration)

novatek pharmaceuticals ltd. - dexlansoprazole - capsule - 60 mg